Biodel Inc. (Nasdaq: BIOD) today announced plans to present clinical results of its leading product candidate, VIAject(TM), at the 67th Annual American Diabetes Association (ADA) Scientific Sessions, to be held in Chicago, June 22 through June 26. [click link for full article]
More...